Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the ...

The "United States Oral Solid Dosage Contract Manufacturing Market, By Region, Competition, Forecast & Opportunities, ...

AbbVie will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of ...

Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Drugmakers have greeted 2025, implementing price hikes for 583 products within the first two days of the new year, according ...